The international projects office of the IIS Aragón has created this monthly newsletter through which it will inform about the calls for projects that are open, the events and the conferences that may be interesting in this regard for the research and management staff.
If you want to contact the international projects office you can do so through this email address:
international@iisaragon.es
The ISIDORe project proposes to fund Research & Development into preparedness and responsiveness, by giving scientific communities, free-of-charge transnational access (TNA)
to the full extent of our state-of-the-art facilities, cutting-edge services, advanced equipment and technologies, made available through our catalog of services.
IARC Summer School 2023 Call for Applications is Open
The International Agency for Research on Cancer (IARC) is pleased to announce that it is now accepting applications for the IARC Summer School 2023, for two modules: "Introduction to Cancer Epidemiology" and "Implementing Cancer Prevention and Early Detection".
The IARC Summer School 2023 provides the opportunity to stimulate cancer research, improve scientific knowledge, and develop collaborations among researchers worldwide. Building on past successful IARC Summer Schools, the two modules in 2023 will be delivered as blended training programs, combining online learning with virtual and in-person classes. The hybrid format will offer the best of remote learning and the unmatched value of relationships formed during face-to-face events and their effect on boosting network-building and future collaborations.
Those who want to attend the summer school module on "Implementing Cancer Prevention and Early Detection" should first take the self-paced course on cancer prevention and early detection, which is available on the IARC Learning portal. This self-paced learning path will take participants through various resources, which cover the basic concepts and principles related to cancer prevention and early detection. See the links below for more information.
Horizon Europe – ERC Proof of Concept Grant
(ERC-2023-POC)
Horizon Europe – ERC Proof of Concept Grant (ERC-2023-POC)
The ERC Proof of Concept Grants aim at facilitating exploration of the commercial and social innovation potential of ERC funded research, by funding further work (ie activities which were not scheduled to be funded by the original ERC frontier research grant) to verify the innovation potential of ideas arising from ERC funded projects. Proof of Concept Grants are therefore on offer only to Principal Investigators whose proposals draw substantially on their ERC funded research.
The financial contribution will be awarded as a lump sum of EUR 150
for a period of 18 months. The ERC expects that, normally, proof of concept activities should be completed within 12 months. However, to allow for those projects that require more preparation time, the grant agreements will be signed for 18 months. Extensions of the duration of proof of concept projects may be granted only exceptionally. The lump sum will cover the beneficiaries' direct and indirect eligible costs for the project: if the project is implemented properly, the amounts will be paid regardless of the costs actually incurred . The lump sum has been designed to cover the beneficiaries' personnel costs, subcontracting, purchase costs, other cost categories, and indirect costs.
All Principal Investigators in an ongoing ERC main grant or in an ERC main grant that has ended less than 12 months before 1 January 2023, are eligible to apply for an ERC Proof of Concept Grant.
ATTRACT-Call: Accelerate Together Rare Cancer Treatment
Five European anti-cancer funds, including the Scientific Foundation of the Spanish Association Against Cancer, are coming together to stimulate international research for the development of drugs against rare cancers.
This joint international call, ATTRACT-Call, focuses on phase 2/3 clinical trials of drugs against rare cancers, and has a budget of €11,5 million.
Objectives:
- Improve treatment of rare cancers
- Take the drugs to the next phase of Development
Horizon Europe – ERC Consolidator Grant
(ERC-2023-COG)
The ERC Consolidator Grants are designed to support excellent Principal Investigators at the career stage at which they may still be consolidating their own independent research team or programme. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.
Consolidator Grants may be awarded up to a maximum of EUR 2
for a period of 5 years. The maximum size of the grants is reduced pro rata temporis for projects of a shorter duration. (This does not apply to ongoing projects).
The Principal Investigators shall have been awarded their first PhD at least 7 and up to 12 years prior to 1 January 2023. Cut-off dates: PhD awarded from 1 January 2011 to 31 December 2015 (inclusive).
Call for Transnational Projects with participation of the State Research Agency within the framework of “ERA4Health Partnership”.
Spain participates in the second transnational call of the ERA4Health Partnership initiative “Fostering a European Research Area for Health”, through the State Research Agency (AEI), the Carlos III Health Institute (ISCIII) and the Ministry of Health and Consumer Affairs of the Junta de Andalucía (CSCJA).
The general objective of the call is to support transversal research that contributes to the development of therapeutic innovation strategies in cardiovascular diseases, addressing one (or both) of the following research areas:
1- Repair and/or regeneration of the heart and/or blood vessels.
2-Chronic heart failure and atrial fibrillation.
Call for Proposals 2023: «Natural History Studies addressing unmet needs in Rare Diseases»
The objective of this call is to conduct efficient, innovative and high-quality natural history studies which will facilitate understanding of the disease's or group of disorders' progression throughout the lifespan of a patient. The goal of these studies is to collect and analyze comprehensive patient data to define targets for future therapies, taking into consideration innovation, safety, and efficacy.
Research proposals should cover at least one of the following areas:
1- Estimation of disease prevalence;
2- Identification of biomarkers/companions for the diagnosis/prognosis of a RD;
3- Identification of biomarkers/indicators/predictors of a rare disease or group of disorders (eg having the same aetiology) onset/progression (including collection of genetic, physiological, environmental data or variables….);
4- Identification of relevant endpoints for future studies that include potential biomarkers, querying patient-reported outcomes (PROs) and quality-of-life measures;
5- Identification of biomarkers/variables for therapeutic approaches (pharmacology, drug repurposing, gene therapy, RNA therapy, cell therapy, medical devices...).
MSCA COFUND co-finances new or existing doctoral programs and postdoctoral fellowship schemes with the aim of spreading the best practices of the MSCA including international, inter-sectoral and interdisciplinary research training, as well as international and cross-sectoral mobility of researchers at all stages of their career.
In practice, MSCA COFUND provides complementary funding for doctoral or postdoctoral programs managed by entities established in EU Member States or Horizon Europe Associated Countries. Those co-funded programs must follow MSCA's good practice in terms of international recruitment and minimum standard of employment for the recruited fellows as described in the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers.
Opening date: 11/10/2022
EU4H-2022-PJ-11: Call for proposals on prevention of NCDs - cardiovascular diseases, diabetes and other NCDs EU4H-2022-PJ-12: Call for proposals on cancer and other NCDs prevention – action on health determinants EU4H-2022-PJ-14: Call for proposals to support the roll-out of the second cohort of the inter-speciality cancer training program
Call for proposals for Mechanisms of Resilience and Vulnerability to Environmental Challenges in Mental Health.
The aim of the call is to facilitate multinational, collaborative research projects that will address critical translational questions to improve our knowledge concerning neurobiological mechanisms involved in resilience or vulnerability to environmental challenges in mental health.
(Call opens 10 January 2023) AMR Diagnostics and Surveillance 2023
Proposals should aim to address unmet needs in the AMR diagnostics and surveillance sectors beyond the current state of the art, by focusing on one of the topics
of the call:
• Topic 1: To develop novel, or improve existing, diagnostics, including point of care diagnostics, that can rule out antimicrobial use or help identify the most effective antimicrobial treatment.
• Topic 2: To develop or improve existing strategies, technologies or methods, or data use strategies to support One Health AMR surveillance.
MSCA Staff Exchanges promote innovative international, inter-sectoral and interdisciplinary collaboration in research and innovation through exchanging staff and sharing knowledge and ideas at all stages of the innovation chain. The scheme fosters a shared culture of research and innovation that welcomes and rewards creativity and entrepreneurship and helps turn ideas into innovative products, services or processes. It is open to research, technical, administrative, and managerial staff supporting R&I activities.
Horizon Europe – Research infrastructure services to support health research, accelerate the green and digital transformation, and advance frontier knowledge (2023) (INFRASERV)
HORIZON-INFRA-2023-SERV-01-01: Research infrastructure services to enable R&I addressing main challenges and EU priorities.
For RI services for improving clinical research in the pediatric area
• advancement of pediatric medicines and other therapeutic and diagnostic approaches for this population group to markets and towards clinical use;
• accelerated availability of solutions and products to pediatric patients in need;
• wider access to rationally designed RI services across Europe to underpin the competitiveness of the European industry and of biotech SMEs developing pediatric medicines and treatment and diagnostic devices;
• joining forces of research infrastructures and pediatric competence networks in EU Member States and Associated Countries, to facilitate pediatric research in the context of pertinent EU regulatory environment;
• availability of innovative tools to conduct pediatric clinical trials, for the re-use of population and historical data, and for enhanced data sharing across actors at different care levels and across regions in Europe.
ERA4Health
Call for transnational research proposalsIncreasing health equity through promoting healthy diets and physical activity (HealthEquity)"
The aim of this call is to develop novel strategies and targeted approaches to identify, understand, and modify determinants and mechanisms of diet-related behavior and physical activity as well as sedentary behavior, which have the potential to break through the cycles maintaining unhealthy behaviors and lifestyles and to reduce health inequalities.
The call will be announced on 13/01/2023
and the submission system will be open on the same day.
•
HORIZON-THU-IHI-2022-03-01: Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need
• HORIZON-THU-IHI-2022-03-02: Patient-generated evidence to improve outcomes, support decision making, and accelerate innovation
• HORIZON-THU-IHI-2022-03-03: Combining hospital interventional approaches to improve patient outcomes and increase hospital efficiency
• HORIZON-THU-IHI-2022-03-04: Strengthening the European translational research ecosystem for advanced therapeutic medicinal products (ATMPs) for rare diseases
• HORIZON-THU-IHI-2022-03-05: Digital health technologies for the prevention and personalized management of mental disorders and their long-term health consequences.
Applicant consortia must ensure that at least 45% of the total budget is covered by contributions from project participants.
•
EU4H-2022-PJ-16: Call for proposals to support Member States and other relevant actors to implement relevant results of innovative public health research in relation to vaccination against COVID-19.
•
HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumor-host interactions to enhance immune system-focused treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.
• HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioral change.
• HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics
• HORIZON-MISS-2023-CANCER-01-04: Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions.
• HORIZON-HLTH-2023-ENVHLTH-02-01: Planetary health: understanding the links between environmental degradation and health impacts.
• HORIZON-HLTH-2023-ENVHLTH-02-02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)
• HORIZON-HLTH-2023-ENVHLTH-02-03: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties.
• HORIZON-HLTH-2023-ENVHLTH-02-04: Global coordination of exposome research.
• HORIZON-HLTH-2023-DISEASE-03-01: Novel approaches for palliative and end-of-life care for non-cancer patients.
• HORIZON-HLTH-2023-DISEASE-03-03: Interventions in city environments to reduce risk of non-communicable disease (Global Alliance for Chronic Diseases – GACD)
• HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential.
• HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platforms trials and/or for cohort networks.
• HORIZON-HLTH-2023-DISEASE-03-06: Towards structuring brain health research in Europe.
• HORIZON-HLTH-2023-DISEASE-03-07: Relationship between infections and non-communicable diseases.
• HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response: Understanding vaccine induced-immunity.
• HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response: Immunogenecity of viral proteins of viruses with epidemic and pandemic potential.
Ensuring access to innovative, sustainable and high-quality health care (Single stage -2023) (HORIZON-HLTH-2023-CARE-04)
• HORIZON-HLTH-2023-TOOL-05-01: Clinical trials of combined Advance Therapy Medicinal Products (ATMPs)
• HORIZON-HLTH-2023-TOOL-05-03: Integrated, multi-scale computational models of patient patho-physiology ('virtual twins') for personalized disease management.
• HORIZON-HLTH-2023-TOOL-05-04: Better integration and use of health-related real-world and research data, including genomics, for improved clinical outcomes.
• HORIZON-HLTH-2023-TOOL-05-05: Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centered health and care delivery.
• HORIZON-HLTH-2023-TOOL-05-08: Pandemic preparedness and response: in vitro diagnostic mechanisms to tackle cross-border health threats.
• HORIZON-HLTH-2023-TOOL-05-09: Developing a Data Quality and Utility Label for the European Health Data Space.
• HORIZON-HLTH-2023-IND-06-01: Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU.
• HORIZON-HLTH-2023-IND-06-02: Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space.
• HORIZON-HLTH-2023-IND-06-04: Modeling and simulation to address regulatory needs in the development of orphan and pediatric medicines.
• HORIZON-HLTH-2023-IND-06-05: Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs).
• HORIZON-HLTH-2023-IND-06-07: Development and harmonization of methodologies for assessing digital health technologies in Europe.
•
Topic 1: Expanding translational knowledge in minipigs: a path to reduce and replace non-human primates in non-clinical safety assessment
• Topic 2: Patient-centric blood sample collection to enable decentralized clinical trials and improve access to healthcare
Multinational Research Projects on Ethical, Legal and Social Aspects (ELSA) of Neuroscience.
Research proposals may address, among others, the following topics:
* Consequences of the development of neuroscientific diagnostic methods.
* Diagnosis in the absence of treatment options; interactions between socioculturally diverse patients and healthcare personnel; (equitable) access to novel and expensive methods; unintentional use and/or misuse).
* Aspects of clinical research with patients suffering from neurological or psychiatric diseases.
* Intelligent technologies and close interaction between human and machine.
* Biobanks of neuronal tissues.
* Use of brain data; Brain interventions in legal contexts.
* Impact of modern neuroscience on traditional philosophical questions, concepts and theories about fundamental aspects of human nature.
* Social and cultural changes induced by neuroscientific knowledge and its application.
* Responsible research and innovation in neurotechnology and neuroscience.
The European Commission announces that the Info Day for the EU Missions will be held as a virtual event on Wednesday 17 and Thursday 18 January 2023.
The Cancer Mission session will be held from 14.00-16.00 on Tuesday 17th January.
The Info Day will present the new calls in the Missions' part of the main Work Program 2023 under Horizon Europe.
The sessions will give the opportunity to prospective applicants to learn more about the funding options on Missions through a series of dedicated sessions.
All recordings of the event's sessions will be made available online for future reference.
The aim of the IHI Call Days is to provide potential applicants with the information they need to put together a strong proposal and give them the opportunity to identify and meet partners for their consortia.
The main activities of the Call Days will be as follows:
• Info session on the rules and procedures
• Info sessions on the call topics
Increasing health equity through promoting healthy diets and physical activity – “HealthEquity” – 10:00
Following the recent pre-announcement of the HealthEquity call on research targeting health inequalities through promoting healthy diets and physical activity, ERA4Health invites all potential project applicants to an information webinar.
In the webinar, the call documents and guidelines on how to apply for the call will be presented. ERA4Health will also facilitate networking of applicants.
For participation, please register via the link below, until Wednesday January 18, 2023 EOB.
EJP RD – European Joint Program on Rare Diseases – 13/17-02/2023 12:00 – 17:00 Barcelona, Spain
Registration is now open to the yearly 5-day course on “Translational Medicine Explained (TMex) ” on 13-17 February 2023 in Barcelona. The course is intended for PhD/MD students, postdocs and other young scientists who are involved in biomedical research and want to learn more about Translational Medicine.
The TMex (“Translational Medicine Explained)” Winter School consists of an introductory e-learning (~12 hours student investment time) followed by a 5-day face-to-face workshop. The course is intended for PhD/MD students in the second half of their PhD and postdocs who are involved in biomedical research.
The full fee is €650. Special discounted fees of €475 applies for EATRIS members and I2TRON students, and of €250 for VHIR students and EUPATI fellows.
There are only 30 seats, so we recommend applying early (first come, first served). The registration will close when all seats have been filled. You will need to submit a biosketch and a motivation letter which will be reviewed by a selection committee.
Contact
Aragón Health Research Institute (IIS Aragón)
Biomedical Research Center of Aragon (CIBA)
Avda. San Juan Bosco, nº 13. 50009 - Zaragoza
Tel. +34 976 71 64 17 | +34 976 71 44 02
You receive this newsletter because you are a member of IIS Aragón or because you are interested in its activities. If you do not wish to receive it, please contact international@iisaragon.es
to process the subscription cancellation.